Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-hCD33 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Academia Sinica
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-hCD33 monoclonal antibody (specifically clone 4L3-46) is an antagonistic biologic developed by researchers at Academia Sinica that targets human CD33 (also known as Siglec-3). CD33 is an inhibitory receptor containing an immune-receptor tyrosine-based inhibition motif (ITIM) that typically recruits phosphatases such as SHP-1, SHP-2, and SHIP to exert immunosuppressive effects. While CD33 is a well-established therapeutic target in acute myeloid leukemia (AML) and serves as a marker for myeloid-derived suppressor cells (MDSCs), this specific antibody is being investigated for its potential to treat solid tumors. By blocking CD33 signaling, 4L3-46 aims to restructure the infiltrating MDSC population and reverse CD33-mediated immune evasion, thereby attenuating tumor growth and improving survival outcomes in preclinical models.
- Other names
- anti-CD33 monoclonal antibodyanti-CD-33 monoclonal antibodyanti-CD 33 monoclonal antibodyanti-hCD33 mAbanti-hCD-33 mAbanti-hCD 33 mAb
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on anti-hCD33 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-hCD33 monoclonal antibody.